Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity

Clinical Therapeutics

Volumn 22, Issue 6, 2000, Pages 685-708

  Kakuda, Thomas N ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adverse effects; Anti HIV drugs; DNA polymerase; HIV; Mitochondria; Nucleoside and nucleotide reverse transcriptase inhibitors

Indexed keywords

2',3' DIDEOXY 2' FLUOROADENOSINE; ABACAVIR; ADEFOVIR DIPIVOXIL; ADENOSINE DIPHOSPHATE; ADENOSINE KINASE; ADENYLATE KINASE; DIDANOSINE; DNA DIRECTED DNA POLYMERASE GAMMA; LAMIVUDINE; MITOCHONDRIAL ENZYME; NUCLEOSIDE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

CYTOTOXICITY; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; FATTY LIVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LACTIC ACIDOSIS; LIPODYSTROPHY; LIPOMATOSIS; MITOCHONDRION; MYOPATHY; NEPHROTOXICITY; OTOTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY; REVIEW;

EID: 0033935975     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(00)90004-3     Document Type: Article

References (99)

1. 1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available at: http://www.hivatis.org 2000. Accessed May 15, 2000.
2. 2. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society USA Panel. JAMA. 2000;283:381-390.
3. 3. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med. 1995;333:1662-1669.
4. 4. Fischl MA, Stanley K, Collier AC, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med. 1995;122:24-32.
5. 5. Katlama C, Ingrand D, Loveday C, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy. JAMA. 1996;276:118-125.
6. 6. Delta Coordinating Committee. Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus ddI or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283-291.
7. 7. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per millimeter. N Engl J Med. 1996;335:1081-1090.
8. 8. Saravolatz LD, Winslow DL, Collins C, et al. Zidovudine alone or in combination with ddI or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med. 1996;335:1099-1106.
9. 9. Saag MS, Sonnerborg A, Torres RA, et al. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. AIDS. 1998;12: F203-F209.
10. 10. Ruiz L, Romeu J, Martínez-Picado J, et al. Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC. AIDS. 1996;10:F61-F66.
11. 11. Staszewski S, Katlama C, Harrer T, et al. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects. AIDS. 1998;12:F197-F202.
12. 12. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
13. 13. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med. 1999; 340:1605-1613.
14. 14. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: A looming obstacle for long-term anti-retroviral therapy? Curr Opin Infect Dis. 2000;13:5-11.
15. 15. Scalfaro P, Chesaux JJ, Buchwalder PA, et al. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment. Intensive Care Med. 1998;24:247-250.
16. 16. Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet. 1999;354:1084-1089.
17. 17. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1998;13:465-471.
18. 18. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
19. 19. Madge S, Kinloch-de-Loes S, Mercey D, et al. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS. 1999;13: 735-737.
20. 20. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med. 1995; 1:417-422.
21. 21. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744.
22. 22. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112-1115.
23. 23. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS. 1999;13:2311-2312.
24. 24. Noble S, Goa KL. Adefovir dipivoxil. Drugs. 1999;58:479-487.
25. 25. U.S. Bioscience suspends clinical trial of lodenosine (FddA), 1999. Available at: http://www.usbio.com/1999/99oct14.htm. Accessed May 15, 2000.
26. 26. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
27. 27. Saraste M. Oxidative phosphorylation at the fin de siècle. Science. 1999;283:1488-1493.
28. 28. Johns DR. Mitochondrial DNA and disease. N Engl J Med. 1995;333:638-644.
29. 29. Wallace DC. Mitochondrial diseases in man and mouse. Science. 1999;283:1482-1488.
30. 30. Simon DK, Johns DR. Mitochondrial disorders: Clinical and genetic features. Annu Rev Med. 1999;50:111-127.
31. 31. Chinnery PF, Turnbull DM. Mitochondrial DNA and disease. Lancet. 1999;354:17-21.
32. 32. Balzarini J. Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives. Pharm World Sci. 1994;16:113-126.
33. 33. Rossi L, Serafini S, Schiavano GF, et al. Metabolism, mitochondrial uptake and toxicity of 2′,3′-dideoxycytidine. Biochem J. 1999;344:915-920.
34. 34. Faletto MB, Miller WH, Garvey EP, et al. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. Antimicrob Agents Chemother. 1997;41:1099-1107.
35. 35. Balzarini J, Herdewijn P, De Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T) and 3′-azido-2′,3′-dideoxythymidine (AZT), two potent anti-HIV compounds. J Biol Chem. 1989;264:6127-6133.
36. 36. Bourdais J, Biondi R, Sarfati S, et al. Cellular phosphorylation of anti-HIV nucleosides. J Biol Chem. 1996;271:7887-7890.
37. 37. Gao W-Y, Shirasaka T, Johns DG, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 1993;91: 2326-2333.
38. 38. Gao W-Y, Agbaria R, Driscoll JS, Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 1994;269:12633-12638.
39. 39. Starnes MC, Cheng Y-C. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem. 1987; 262:988-991.
40. 40. Copeland WC, Chen MS, Wang TS. Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J Biol Chem. 1992; 267:21459-21464.
41. 41. Olivero OA, Shearer GM, Chougnet CA, et al. Incorporation of zidovudine into leukocyte DNA from HIV-1-positive adults and pregnant women, and cord blood from infants exposed in utero. AIDS. 1999;13:919-925.
42. 42. Cheng Y-C, Gao W-Y, Chen CH, et al. DNA polymerases versus HIV reverse transcriptase in AIDS therapy. Ann N Y Acad Sci. 1990;616:217-223.
43. 43. Hart GJ, Orr DC, Penn CR, et al. Effects of (-)-2′-deoxy-3′-thiacytidine (lamivudine) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob Agents Chemother. 1992;36:1688-1694.
44. 44. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994;38: 2743-2749.
45. 45. Naviaux RK, Markusic D, Barshop BA, et al. Sensitive assay for mitochondrial DNA polymerase γ. Clin Chem. 1999;45:1725-1733.
46. 46. White EL, Parker WB, Macy LJ, et al. Comparison of the effect of carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. Biochem Biophys Res Commun. 1989;161:393-398.
47. 47. Izuta S, Saneyoshi M, Sakurai T, et al. The 5′-triphosphates of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxynucleosides inhibit DNA polymerase gamma by different mechanisms. Biochem Biophys Res Commun. 1991;179:776-783.
48. 48. Parker WB, White EL, Shaddix SC, et al. Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases α, β, and γ by the 5′-triphosphates of carbovir, 3′-azido-3′-deoxythymidine, 2′,3′-dideoxyguanosine, and 3′-deoxythymidine. J Biol Chem. 1991;266:1754-1762.
49. 49. Lewis W, Simpson JF, Meyer RR. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ Res. 1994;74:344-348.
50. 50. Cherrington JM, Allen SJW, Bischofberger N, Chen MS. Kinetic interaction of the diphosphates of 9-(2-phosphonylmethoxyethyl) adenine and other anti-HIV active purine congeners with HIV reverse transcriptase and human DNA polymerases α, β, and γ. Antiviral Chem Chemother. 1995;6:217-221.
51. 51. Eriksson S, Xu B, Clayton DA. Efficient incorporation of anti-HIV deoxynucleotides by recombinant yeast mitochondrial DNA polymerase. J Biol Chem. 1995;270:18929-18934.
52. 52. Kukhanova M, Li X, Chen S-H, et al. Interaction of β-L-2′,3′-dideoxy-2′,3′-didehydro-5-CTP with human immunodeficiency virus-1 reverse transcriptase and human DNA polymerases: Implications for human immunodeficiency virus drug design. Mol Pharmacol. 1996;53:801-807.
53. 53. Barile M, Valenti D, Hobbs GA, et al. Mechanisms of toxicity of 3′-azido-3′-deoxythymidine. Its interaction with adenylate kinase. Biochem Pharmacol. 1994; 48:1405-1412.
54. 54. Barile M, Valenti D, Passarella S, Quagliariello E. 3′-Azido-3′-deoxythmidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. Biochem Pharmacol. 1997;53:913-920.
55. 55. Modica-Napolitano JS. AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem Biophys Res Commun. 1993;194:170-177.
56. 56. Elimadi A, Morin D, Albengres E, et al. Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylalion. Br J Pharmacol. 1997; 121:1295-1300.
57. 57. Pereira L, Oliveira MBM, Carnieri EGS. Mitochondrial sensitivity to AZT. Cell Biochem Funct. 1998;16:173-181.
58. 58. Chen CH, Vazques-Padua M, Cheng Y-C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implications for delayed toxicity. Mol Pharmacol. 1991;39:625-628.
59. 59. Chen CH, Cheng Y-C. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′,3′-dideoxycytidine. J Biol Chem. 1992;267: 2856-2859.
60. 60. Medina DJ, Tsai CH, Hsiung GD, Cheng YC. Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother. 1994;38:1824-1828.
61. 61. Tsai CH, Doong SL, Johns DG, et al. Effect of anti-HIV 2′-beta-fluoro-2′,3′-dideoxynucleoside analogs on the cellular content of mitochondrial DNA and on lactate production. Biochem Pharmacol. 1994;48:1477-1481.
62. 62. Parker WB, Shaddix SC, Vince R, Bennett LL Jr. Lack of mitochondrial toxicity in CEM cells treated with carbovir. Antiviral Res. 1997;34:131-136.
63. 63. Chen CH, Cheng Y-C. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem. 1989;264:11934-11937.
64. 64. Nusbaum NJ, Joseph PE. AZT incorporation into mitochondria: Study in a human myeloid cell line. DNA Cell Biol. 1996; 15:363-366.
65. 65. Hobbs GA, Keilbaugh SA, Simpson MV. The Friend murine erythroleukemia cell, a model system for studying the association between bone marrow toxicity induced by 3′-azido-3′-dideoxythymidine and dideoxynucleoside inhibition of mtDNA replication. Biochem Pharmacol. 1992;43: 1397-1400.
66. 66. Hobbs GA, Keilbaugh SA, Rief PM, Simpson MV. Cellular targets of 3′-azido-3′-deoxythymidine: An early (non-delayed) effect on oxidative phosphorylation. Biochem Pharmacol. 1995;50:381-390.
67. 67. Herzberg NH, Zorn I, Zwart R, et al. Major growth reduction and minor decrease in mitochondrial enzyme activity in cultured human muscle cells after exposure to zidovudine. Muscle Nerve. 1992;15:706-710.
68. 68. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. Part I: L-carnitine prevents the myotoxicity of AZT in vitro. Lab Invest. 1994;71:102-112.
69. 69. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: Treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Lab Invest. 1994;71:773-781.
70. 70. Benbrik E, Chariot P, Bonavaud S, et al. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J Neurol Sci. 1997;149:19-25.
71. 71. Keilbaugh SA, Hobbs GA, Simpson MV. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: Prevention of 2′,3′-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate. Mol Pharmacol. 1993; 44:702-706.
72. 72. Keilbaugh SA, Hobbs GA, Simpson MV. Effect of 2′,3′-dideoxycytidine on oxidative phosphorylation in the PC12 cell, a neuronal model. Biochem Pharmacol. 1997;53:1485-1492.
73. 73. Cui L, Locatelli L, Xie MY, Sommadossi JP. Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells. J Pharmacol Exp Ther. 1997;280:1228-1234.
74. 74. Wang H, Lemire BD, Cass CE, et al. Zidovudine and dideoxynucleosides deplete wild-type mitochondrial DNA levels and increase deleted mitochondrial DNA levels in cultured Kearns-Sayre syndrome fibroblasts. Biochim Biophys Acta. 1996;1316:51-59.
75. 75. Schroder JM, Kaldenbach T, Piroth W. Nuclear and mitochondrial changes of cocultivated spinal cord, spinal ganglia and muscle fibers following treatment with various doses of zidovudine. Acta Neuropathol. 1996;92:138-149.
76. 76. Lewis W, Papoian T, Gonzalez B, et al. Mitochondrial ultrastructural and molecular changes induced by zidovudine in rat hearts. Lab Invest. 1991;65:228-236.
77. 77. Youssef JA, Badr MZ. Disruption of mitochondrial energetics and DNA synthesis by the anti-AIDS drug dideoxyinosine. Toxicol Lett. 1992;60:197-202.
78. 78. Feldman D, Anderson TD. Schwann cell mitochondrial alterations in peripheral nerves of rabbits treated with 2′,3′-dideoxycytidine. Acta Neuropathol. 1994;87:71-80.
79. 79. Linnane AW, Degli Esposti M, Generowicz M, et al. The universality of bioenergetic disease and amelioration with redox therapy. Biochim Biophys Acta. 1995; 1271:191-194.
80. 80. Corcuera T, Alonso MJ, Picazo A, et al. Hepatic morphological alterations induced by zidovudine (ZDV) in an experimental model. Pathol Res Pract. 1996;192: 182-187.
81. 81. de la Asuncion JG, del Olmo ML, Sastre J, et al. Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver. Hepatology. 1999;29:985-987.
82. 82. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals: Risk factors, incidence and management. Drug Saf. 1998;19:481-494.
83. 83. Gasnault J, Pinganaud C, Kousignian P, et al. Subacute ascendant polyneuropathy revealing a nucleoside-induced mitochondrial cytopathy. Presented at: The Seventh European Conference on Clinical Aspects and Treatment of HIV Infection; October 23-27, 1999; Lisbon, Portugal.
84. 84. Cooney DA, Dalal M, Mitsuya H, et al. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol. 1986;35:2065-2068.
85. 85. Marra CM, Wechkin HA, Longstreh WT Jr, et al. Hearing loss and antiretroviral therapy in patients infected with HIV-1. Arch Neurol. 1997;54:407-410.
86. 86. Perry CM, Balfour JA. Didanosine: An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs. 1996;52:928-962.
87. 87. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: A review. Am J Med. 1999;107:78-84.
88. 88. Yarchoan R, Lietzau JA, Nguyen BY, et al. A randomized pilot study of alternating or simultaneous zidovudine and ddI therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis. 1994;169:9-17.
89. 89. Allaouchiche B, Duflo F, Cotte L, et al. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on ddI therapy. J Antimicrob Chemother. 1999; 44:137-138.
90. 90. Hurst M, Noble S. Stavudine: An update of its use in the treatment of HIV infection. Drugs. 1999;58:919-949.
91. 91. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA. 1999;282:2305-2312.
92. 92. Hayakawa M, Ogawa T, Sugiyama S, et al. Massive conversion of guanosine to 8-hydroxy-guanosine in mouse liver mitochondrial DNA by administration of azidothymidine. Biochem Biophys Res Commun. 1991;176:87-93.
93. 93. Mhiri C, Baudrimont M, Bonne G, et al. Zidovudine myopathy: A distinctive disorder associated with mitochondrial dysfunction. Ann Neurol. 1991;29:606-614.
94. 94. Corcuera Pindado MT, Lopez Bravo A, Martinez-Rodriguez R, et al. Histochemical and ultrastructural changes induced by zidovudine in mitochondria of rat cardiac muscle. Eur J Histochem. 1994;38:311-318.
95. 95. Thornberry NA, Lazebnik Y. Caspases: Enemies within. Science. 1998;281:1312-1316.
96. 96. Leoni LM, Chao Q, Cottam HB, et al. Induction of an apoptotic program in cell-free extracts by 2-chloro-2′-deoxyadenosine 5′-triphosphate and cytochrome c. Proc Natl Acad Sci USA. 1998;95:9567-9571.
97. 97. Hashimoto K-I, Tsunoda R, Okamoto M, et al. Stavudine selectively induces apoptosis in HIV type 1-infected cells. AIDS Res Hum Retroviruses. 1997;13:193-199.
98. 98. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS. 1999;13:2261-2267.
99. 99. Lori F. Hydroxyurea and HIV: 5 years later - from antiviral to immune-modulating effects. AIDS. 1999;13:1433-1442.